Pfizer sues Amgen in effort to invalidate top cancer drug patent

Pfizer is suing Amgen in Europe over a patent issue, one in which both companies have long gone back and forth. The brouhaha centers around Amgen’s cancer drug Neulasta, which has faced increasing biosimilar competition over the years. Though the two companies settled a suit in March regarding the drug’s…

Click to view original post